OCX Oncocyte

Oncocyte To Announce First Quarter 2023 Financial Results

Oncocyte To Announce First Quarter 2023 Financial Results

Conference Call on Thursday, May 11 at 6:00 a.m. PT / 9:00 a.m. ET

IRVINE, Calif., April 27, 2023 (GLOBE NEWSWIRE) --  (Nasdaq: OCX), a precision diagnostics company, announced today that it will release its first quarter 2023 financial results on Thursday, May 11, 2023, before U.S. market open. The company will host a conference call following the release at 6:00 a.m. Pacific Time / 9:00 a.m. Eastern Time to discuss its financial results and recent highlights.

Interested parties may access the live call via telephone by dialing (877) 317-6789 for domestic callers or (412) 317-6789 for international callers. Once dialed in ask to be joined to the Oncocyte Corporation call. The live webinar of the call may be accessed by visiting the “Events & Presentation” section of the Company’s website at . A replay of the webinar will be available on the Company’s website shortly after the conclusion of the call.

About Oncocyte

Oncocyte is a precision diagnostics company. The Company’s tests are designed to help provide clarity and confidence to physicians and their patients. DetermaIO™ is a gene expression test that assesses the tumor microenvironment to predict response to immunotherapies. VitaGraft™ is a blood-based solid organ transplantation monitoring test, and pipeline test DetermaCNI™ is blood-based monitoring tool for monitoring therapeutic efficacy. For more information, visit

DetermaIO™, DetermaCNI™, and VitaGraft™ are trademarks of Oncocyte Corporation.

Investor Contact

Jesse Arno

(949) 409-6770



EN
27/04/2023

Underlying

OCXOncocyte

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on Oncocyte

 PRESS RELEASE
Free
OCX ONCOCYTE

IMDX Reports Q3 2025 Results and Progress Toward 2026 Commercial Launc...

IMDX Reports Q3 2025 Results and Progress Toward 2026 Commercial Launch On track to submit GraftAssureDx™ for FDA review by year-endOn track for commitment to have 20 transplant centers globally engaged with GraftAssure technology by end of 2025GraftAssure assay’s head-to-head data continue to be favorablePreparing to rapidly expand beyond kidney into heart transplant testing NASHVILLE, Tenn., Nov. 10, 2025 (GLOBE NEWSWIRE) -- Insight Molecular Diagnostics Inc., or iMDx, (Nasdaq: IMDX), today published the following letter to shareholders in conjunction with its third quarter results:  ...

November 10, 2025 1 EN
 PRESS RELEASE
Free
OCX ONCOCYTE

iMDx to Release Third Quarter 2025 Results on November 10 and Attend S...

iMDx to Release Third Quarter 2025 Results on November 10 and Attend Stephens Annual Investment Conference the Following Week NASHVILLE, Tenn., Nov. 03, 2025 (GLOBE NEWSWIRE) -- Insight Molecular Diagnostics Inc., (Nasdaq: IMDX), (iMDx), today announced that it will report third quarter 2025 financial results after the market closes on Monday, November 10, 2025. iMDx will host a live Zoom webinar to discuss the company's financial results at 2:00 pm PT / 5:00 pm ET that same day. The live webinar to discuss financial results, followed by Q&A, will be accessible via registration at the fo...

November 3, 2025 1 EN
 PRESS RELEASE
Free
OCX ONCOCYTE

iMDx Welcomes New VP Marketing to Prepare for Commercial Transplant As...

iMDx Welcomes New VP Marketing to Prepare for Commercial Transplant Assay Launch Steven Tahmooressi to lead global marketing efforts for GraftAssure family of assays and future productsBrings 25 years of experience driving new product adoption across geographies in transplantation, oncology and immunology NASHVILLE, Tenn., Oct. 13, 2025 (GLOBE NEWSWIRE) -- Insight Molecular Diagnostics Inc., (Nasdaq: IMDX), (iMDx), today announced that it has welcomed Steven Tahmooressi to its executive leadership team as the company prepares to launch its first clinical kitted assay in 2026. As Vice ...

October 13, 2025 1 EN
 PRESS RELEASE
Free
OCX ONCOCYTE

iMDx Reports Kidney Transplant Patient Achieved ‘Immune Reset’ with No...

iMDx Reports Kidney Transplant Patient Achieved ‘Immune Reset’ with Novel Therapy and GraftAssure Monitoring American Journal of Transplantation study positions GraftAssure as potentially essential in managing immunosuppression treatment in kidney transplant patients with certain cancersGraftAssure used to help avoid overtreatment and preserve patient’s immune systemAs transplant care evolves to include novel therapies, the need for ongoing molecular diagnostic monitoring should continue to grow NASHVILLE, Tenn., Oct. 06, 2025 (GLOBE NEWSWIRE) -- Insight Molecular Diagnostics Inc., (Nasd...

October 6, 2025 1 EN
 PRESS RELEASE
Free
OCX ONCOCYTE

Insight Molecular Diagnostics to Showcase Leadership in Kidney Transpl...

Insight Molecular Diagnostics to Showcase Leadership in Kidney Transplant Management at Conferences in Singapore and Orlando IMDX to host symposium on Wednesday, September 24th to discuss GraftAssureIQ™ at International Association of Therapeutic Drug Monitoring and Clinical Toxicology (IATDMCT) annual meetingPresenting on GraftAssureIQ at symposium on Thursday, October 9th at the American Society of Histocompatibility and Immunogenetics (ASHI) annual meeting NASHVILLE, Tenn., Sept. 24, 2025 (GLOBE NEWSWIRE) -- Insight Molecular Diagnostics Inc., (Nasdaq: IMDX), (iMDx), today announced...

September 24, 2025 1 EN

ResearchPool Subscriptions

Get the most out of your insights

Get in touch